Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),
BORDEAUX, France (BUSINESS WIRE) Regulatory News:Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the « Company »), informs its shareholders and the financial community that the Company’s Ordinary Gene.
Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the
Regulatory News: Aelis Farma (ISIN code: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases (the Company »),
16.02.2022 - Regulatory News: Aelis Farma (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases (the Company ), announces today the successful completion of its initial public offering on .